By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Dudum is still the largest individual holder of Hims & Hers’ stock, owning about 8 million shares indirectly through various ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

SAN FRANCISCO, CA / ACCESS Newswire / July 16, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.